ALLMedicine™ Alopecia Areata Center

Mar 16th, 2023 - There is growing evidence that patients with alopecia areata (AA) have an increased risk of developing psychiatric comorbidities. However, the relationship between AA and suicidal behaviors remains unclear. To investigate the association between A...

Mar 9th, 2023 - Poor therapeutic results have been reported in patients with alopecia areata totalis (AT) or universalis (AU), the most severe and disabling types of alopecia areata (AA). Methotrexate, an inexpensive treatment, might be effective in AU and AT. To...

Mar 2nd, 2023 - The oral Janus kinase (JAK) inhibitor baricitinib has demonstrated efficacy for severe alopecia areata (AA) over 36 weeks. There are limited data on the longer-term treatment of AA. The aim of this study was to evaluate the efficacy and safety of ...

Mar 2nd, 2023 - Alopecia areata (AA) is characterized by nonscarring hair loss of the scalp, face, and/or body. Alopecia totalis (AT) and alopecia universalis (AU) involve complete loss of the scalp and body hair, respectively. The epidemiology of AA in the US re...

Mar 2nd, 2023 - Prevalences of alopecia areata (AA), alopecia totalis (AT), and alopecia universalis (AU) are poorly established. To estimate overall and subgroup prevalences of AA and its subtypes. This cross-sectional study using electronic records comprising t...

Sep 29th, 2022 - Treatment with deuruxolitinib and ritlecitinib, two investigational Janus kinase (JAK) inhibitors, resulted in substantial regrowth of scalp hair for patients with alopecia areata (AA) in separate studies reported at the European Academy of Dermat...

Jul 1st, 2022 - Dermatologists, who recently celebrated the US Food and Drug Administration's (FDA's) approval of the world's first oral systemic treatment for adults with severe alopecia areata (AA), are now looking ahead to the practicalities of getting the dru...

May 20th, 2022 - The European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended approval of baricitinib, a Janus kinase (JAK) inhibitor, for the treatment of adults with severe alopecia areata (AA). The development, whi...

Feb 14th, 2022 - Oral tofacitinib (Xeljanz), a JAK inhibitor, helped regrow hair in three quarters of pediatric patients with alopecia areata (AA) in a small study conducted at the University of Colorado and published in Pediatric Dermatology. The 11 pediatric pat...

Nov 3rd, 2021 - Alopecia areata (AA), an autoimmune disease that causes hair loss, including baldness, has been linked to a significantly increased risk for dementia, new research shows. After controlling for an array of potential confounders, investigators found...